NK cells plus GD2 antibody for high-risk neuroblastoma
Part of Cancer clinical trials.
This trial tests whether combining your child's own immune cells (NK cells) with a targeted antibody (GD2) can help treat high-risk neuroblastoma. It is for children who are in the maintenance phase, or whose cancer has returned or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 18 years old.
- Your child must have high-risk neuroblastoma — either starting maintenance therapy, relapsed, or not responding to treatment.
- If the cancer has come back or is resistant, there must be at least one tumor that can be measured on a scan.
- Your child's major organs (blood, heart, lungs, kidneys, liver) must be working well enough — your doctor can confirm this with tests.
- No active serious infections, and no history of HIV or organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This early-phase trial tests an immune-cell treatment made from the child’s own cells, designed to attack neuroblastoma. It aims to help children whose cancer has come back or did not respond to standard treatment.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.